This newsletter presents you the following key sessions:
1. PODCAST with dr. Zev Wainberg about preliminary data from a phase 1b trial evaluating the safety and
efficacy of tiragolumab combined with atezolizumab for patients with metastatic oesophageal cancer
2. Positive Health-Related Quality of Life outcomes with pembrolizumab monotherapy in unresectable
or metastatic MSI-H/dMMR solid tumours
3. The MODUL study: biomarker-driven maintenance therapy following first-line standard induction
treatment of metastatic colorectal cancer
4. Tislelizumab has a potential in the second-line treatment for patients with advanced or metastatic
squamous oesophageal cell carcinoma
5. Gut microbiome to predict survival time in advanced gastric cancer treated with nivolumab